Alternative dosing schedules for sunitinib as a treatment of patients with metastatic renal cell carcinoma

Critical Reviews in Oncology/Hematology

Volumn 92, Issue 3, 2014, Pages 208-217

  Guida, Fancesco Maria ^a   Santoni, Matteo ^b   Conti, Alessandro ^b   Burattini, Luciano ^b   Savini, Agnese ^b   Zeppola, Tea ^a   Caricato, Marco ^a   Cascinu, Stefano ^b   Tonini, Giuseppe ^a   Santini, Daniele ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Alternative schedule; Metastatic renal cell carcinoma; Sunitinib; Two weeks on one week off

Indexed keywords

SUNITINIB; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PYRROLE DERIVATIVE;

ADULT; AGED; ANEMIA; ANOREXIA; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CARDIOTOXICITY; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; KIDNEY METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; NEUTROPENIA; ORAL MUCOSITIS; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; REVIEW; CARCINOMA, RENAL CELL; DRUG ADMINISTRATION; KIDNEY NEOPLASMS; META ANALYSIS; METASTASIS; PATHOLOGY; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DRUG ADMINISTRATION SCHEDULE; HUMANS; INDOLES; KIDNEY NEOPLASMS; NEOPLASM METASTASIS; PYRROLES; TREATMENT OUTCOME;

EID: 84912523070     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2014.07.006     Document Type: Review

References (32)

1. Kaelin W.G Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2002, 2:673-682.
2. Faivre S., Demetri G., Sargent W., Raymond E. Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 2007, 6:734-745.
3. Rosen L.S., Bello C.L., Mulay M., Dinolfo M., Baum C. A phase I study evaluating administration of oral SU11248 (sunitinib malate) using a loading and maintenance dose on a 2/1 schedule in patients (pts) with advanced solid tumors. Proc Am Assoc Cancer Res 2006, 47:684.
4. Faivre S., Delbaldo C., Vera K., Robert C., Lozahic S., Lassau N., et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006, 24:25-35.
5. Motzer R.J., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Rixe O., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356:115-124.
6. Motzer R.J., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Oudard S., et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009, 27:3584-3590.
7. Gore M.E., Sczylik C., Porta C., Bracarda S., Bjarnason G.A., Oudard S., et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 2009, 10:757-763.
8. Shepard D.R., Garcia J.A. Toxicity associated with the long-term use of targeted therapies in patients with advanced renal cell carcinoma. Expert Rev Anticancer Ther 2009, 9:795-805.
9. Yoo C., Kim J.E., Lee J.L., Ahn J.H., Lee D.H., Lee J.S., et al. The efficacy and safety of Sunitinib in Korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction. Jpn J Clin Oncol 2010, 40:980-985.
10. Bjarnason G.A., Khalil B., Hudson J.M., Williams R., Milot L.M., Atri M., et al. Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: correlation with dynamic microbubble ultrasound data and review of the literature. Urol Oncol 2014, 32:480-487.
11. Neri B., Vannini A., Brugia M., Muto A., Rangan S., Rediti M., et al. Biweekly sunitinib regimen reduces toxicity and retains efficacy in metastatic renal cell carcinoma: a single-center experience with 31 patients. Int J Urol 2013, 20:478-483.
12. Neri B., Vannini A., Tassi R., Brugia M., Rangan S., Rediti M., Cerullo C. The efficacy and tolerability of a sunitinib 3-week administration schedule in metastatic renal cell carcinoma patients: report of three cases. Oncol Res 2012, 20:259-264.
13. Atkinson B.J., Perpich J., Tannir N.M., Jonasch E. Schedule modifications and treatment outcomes for sunitinib-related adverse events. J Clin Oncol 2010, 28:e15115. [abstract].
14. Atkinson B.J., Kalra S., Wang X., Tannir N.M., Jonasch E. Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules. J Urol 2014, 191:611-618.
15. Kletas V., Cheng W., Kollmannsberger C.K., Law De Lemos M., Man S. A population-based analysis of overall survival associated with sunitinib given as intermittent, continuous, or nonconventional individualized dosing regimens for metastatic renal cell carcinoma. J Clin Oncol 2013, 31:e15541. [abstract].
16. Bracarda S., Iacovelli R., Rizzo M., Rossi M., Galli L., Procopio G., et al. Retrospective observational study of sunitinib administered on schedule 2/1 in patients with metastatic renal cell carcinoma (mRCC): the rainbow study. J Clin Oncol 2014, 32. [abstract 471].
17. Najjar Y.G., Mittal K., Elson P., Wood L., Garcia J.A., Dreicer R., Rini B.I. A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma. Eur J Cancer 2014, 50:1084-1089.
18. Motzer R.J., Hutson T.E., Olsen M.R., Hudes G.R., Burke J.M., Edenfield W.J., et al. Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol 2012, 30:1371-1377.
19. Escudier B., Roigas J., Gillessen S., Harmenberg U., Srinivas S., Mulder S.F., et al. Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol 2009, 27:4068-4075.
20. Barrios C.H., Hernandez-Barajas D., Brown M.P., Lee S.H., Fein L., Liu J.H., et al. Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma. Cancer 2012, 118:1252-1259.
21. Yildiz I., Sen F., Basaran M., Ekenel M., Agaoglu F., Darendeliler E., et al. Response rates and adverse effects of continuous once-daily sunitinib in patients with advanced renal cell carcinoma: a singlecenter study in Turkey. Jpn J Clin Oncol 2011, 41:1380-1387.
22. Johannsen M., Florcken A., Bex A., Roigas J., Cosentino M., Ficarra V., et al. Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis. Eur Urol 2009, 55:1430-1438.
23. Rini B.I., Wood L.S., Elson P., Zhu H., Chittoria N., Mittal K., et al. A phase II study of intermittent sunitinib (S) in previously untreated patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2013, 31. [abstr 4515].
24. Collinson F.J., Gregory W.M., McCabe C., Howard H., Lowe C., et al. The STAR trial protocol: a randomised multi-stage phase II/III study of sunitinib comparing temporary cessation with allowing continuation, at the time of maximal radiological response, in the first-line treatment of locally advanced/metastatic renal cancer. BMC Cancer 2012, 12:598.
25. Buti S., Donini M., Lazzarelli S., Passalacqua R. A new modified schedule of sunitinib for metastatic renal cell carcinoma: a retrospective analysis. Acta Biomed 2012, 83:88-94.
26. Wolter P., Beuselinck B., Pans S., Schöffski P. Flare-up: an often unreported phenomenon nevertheless familiar to oncologists prescribing tyrosine kinase inhibitors. Acta Oncol 2009, 48:621-624.
27. Houk B.E., Bello C.L., Poland B., Rosen L.S., Demetri G.D., Motzer R.J. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol 2010, 66:357-371.
28. Houk B.E., Bello C.L., Kang D., Amantea M. A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients. Clin Cancer Res 2009, 15:2497-2506.
29. Rini B.I., Cohen D.P., Lu D.R., Chen I., Hariharan S., Gore M.E., et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2011, 103:763-773.
30. Riesenbeck L.M., Bierer S., Hoffmeister I., Köpke T., Papavassilis P., Hertle L., et al. Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib. World J Urol 2011, 29:807-813.
31. Rini B.I., Melichar B., Ueda T., Grünwald V., Fishman M.N., Arranz J.A., et al. Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial. Lancet Oncol 2013, 14:1233-1242.
32. Rini B.I., Escudier B.J., Michaelson M.D., Negrier S., Gore M.E., Oudard S., et al. Phase III AXIS trial for second-line metastatic renal cell carcinoma (mRCC): effect of prior first-line treatment duration and axitinib dose titration on axitinib efficacy. J Clin Oncol 2012, 30. (abstract 354).